[The Possibilities of Pharmacological Correction of Endothelial Dysfunction in Patients With Arterial Hypertension].
To assess the possibility of a fixed combination of perindopril arginine and amlodipine in the correction of endothelial dysfunction (ED) in patients with arterial hypertension (AH). The study included 49 patients with hypertension and ED receiving any antihypertensive therapy and have not reached the target level of blood pressure--blood pressure (66% women, 34% men). The mean age was 46.2 ± 5.4 years. Patients switching to visit prescribed combination of perindopril arginine and amlodipine in different dosages depending on the level of blood pressure. The study lasted 12 weeks, on the first and last visit was assessed endothelial function. All patients completed the study. Mean systolic and diastolic blood pressure decreased during the 12 weeks to 162.6 ±11.4 to 131.1 ± 10.0 mmHg and 95.4 ± 10.2 to 78.7 ± 7.7 mm Hg respectively (p < 0.05). At the time of the telephone contact was a target mean arterial pressure (p > 0.05). The structure of the DE before the study was as follows: DE major arteries or resistance--28.6%; DE both types--71.4%. After 12 weeks in patients receiving the drug in only 57.1% of the subjects had both types of ED (p < 0.05), DE or large resistive arteries was recorded in 21.4% of patients, while 21.5% were no signs of ED. The number of patients with hypertension who have reached the target blood pressure in patients receiving perindopril arginine and amlodipine increased from visit to visit, and reached 71.4% at 12 weeks. Over the 12 weeks of treatment adverse events occurred only in 2.1-4.2% of cases. Combination therapy with ACE inhibitor perindopril arginine and a calcium channel blocker amlodipine in people of working age with hypertension and ED for 12 weeks leads to a reduction of endothelial dysfunction of large and small vessels (from 71.4 to 57.1%), a significant reduction in systolic and diastolic blood pressure and achieve target blood pressure in 71.4% of cases.